Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Jing Xu, Qisu Zhang, MPH, Mehul Dalal, PhD

Blood (2019) 134 (Supplement_1): 4751.

https://doi.org/10.1182/blood-2019-129053

Published: 2019

Journal Articles

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia

Moshe Yair Levy, MD, Lin Xie, MA, MS, Yuexi Wang, Frank Neumann, MD PhD, Shouryadeep Srivastava, MBBS, PhD, Daniel Naranjo, Qisu Zhang, Mehul Dalal, PhD

Blood (2018) 132 (Supplement 1): 3567.

https://doi.org/10.1182/blood-2018-99-113490

Published: 2018

Journal Articles

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2017) 130 (Supplement 1): 2896.

https://doi.org/10.1182/blood.V130.Suppl_1.2896.2896

Published: 2017

Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Blood (2017) 130 (Supplement 1): 1617.

https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617

Published: 2017

Journal Articles

Cancer Drivers Affected by Aberrant DNA Methylation in MDS and AML

Jaroslav Jelinek, MD, PhD, Shoudan Liang, PhD, Frank Neumann, MD, PhD, Rong He, Yue Lu, PhD, Jumpei Yamazaki, DVM, PhD, Rodolphe F Taby, MD, Louis Ramagli, PhD, Marcos R Estecio, PhD, Jean-Pierre Issa, MD

Blood (2011) 118 (21): 1716.

https://doi.org/10.1182/blood.V118.21.1716.1716

Published: 2011

Journal Articles

SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis,

Animesh Pardanani, MBBS, PhD, Jason Gotlib, M.D., M.S., Catriona Jamieson, Jorge E. Cortes, Moshe Talpaz, Richard Stone, MD, Guozhi Gao, Jenny (Yanzhen) Zhang, MD, PhD, Frank Neumann, MD, PhD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 3838.

https://doi.org/10.1182/blood.V118.21.3838.3838

Published: 2011

Journal Articles

Digital Restriction Enzyme Analysis of Methylation (DREAM) by Next Generation Sequencing Uncovers Epigenetic Disturbances In Acute Myelogenous Leukemia.

Frank Neumann, MD, PhD, Jean-Pierre Issa, MD, Yue Lu, PhD, Marcos R Estecio, PhD, Rong He, Louis Ramagli, PhD, Shoudan Liang, PhD, Jaroslav Jelinek, MD, PhD

Blood (2010) 116 (21): 3635.

https://doi.org/10.1182/blood.V116.21.3635.3635

Published: 2010

Journal Articles

Relevance of HLA-C Epitopes C1 and C2 for the Survival of Patients with AML and CML after Allogeneic Blood Stem Cell Transplantation.

Ingmar Bruns, MD, Akos G. Czibere, MD, Markus Uhrberg, Jürgen Enczmann, MD, Guido Kobbe, MD, Frank Neumann, MD, Peter Wernet, MD, Rainer Haas, MD, Johannes C. Fischer, MD

Blood (2007) 110 (11): 1974.

https://doi.org/10.1182/blood.V110.11.1974.1974

Published: 2007

Journal Articles

Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose Therapy and Autologous Stem Cell Transplantation Is a Prognostic Parameter in Patients with Multiple Myeloma.

Roland Fenk, MD, Mark Korthals, Nina Sehnke, Ingmar Bruns, MD, Akos Czibere, MD, Fabian Zohren, Nancy Safaian, Ariane Dienst, Leilani Ruf, MD, Frank Neumann, MD, Rainer Haas, MD, Ralf Kronenwett, MD, Guido Kobbe, MD

Blood (2007) 110 (11): 1496.

https://doi.org/10.1182/blood.V110.11.1496.1496

Published: 2007

Journal Articles

Transcriptional Changes Induced by Imatinib and Nilotinib in the Chronic Myelogenous Leukemia (CML) Cell Line K562.

Frank Neumann, MD, Daniela C. Bruennert, Anne-Marie Koch, Ingmar Bruns, MD, Norbert Gattermann, MD, PhD, Ralf Kronenwett, MD, PhD, Rainer Haas, MD, PhD

Blood (2007) 110 (11): 4540.

https://doi.org/10.1182/blood.V110.11.4540.4540

Published: 2007

Journal Articles

Sequential Induction Chemotherapy, and Early Intensified Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Myeloid Leukemia.

Thorsten Graef, MD, Nikola Schmittner, Frank Neumann, MD, Roland Fenk, MD, Fabian Zohren, MD, Akos Czibere, MD, Norbert Gattermann, MD, Rainer Haas, MD, Guido Kobbe, MD

Blood (2006) 108 (11): 5367.

https://doi.org/10.1182/blood.V108.11.5367.5367

Published: 2006

Journal Articles

Escalation Treatment Algorithm with Bortezomib, Dexamethasone and Bendamustine for Patients with Relapsed or Refractory Multiple Myeloma: A Singel Centre Experience.

Roland Fenk, MD, Mark Michael, Fabian Zohren, Thorsten Graef, MD, Arkosch Czibere, MD, Sebastian Balleisen, MD, Frank Neumann, MD, Ulrich-Peter Rohr, MD, Ulrich Steidl, MD, Rainer Haas, MD, Guido Kobbe, MD

Blood (2006) 108 (11): 3540.

https://doi.org/10.1182/blood.V108.11.3540.3540

Published: 2006

Journal Articles

Molecular Phenotype of Malignant CD34+ Hematopoietic Stem and Progenitor Cells in Chronic Myelogenous Leukemia.

Ralf Kronenwett, MD, Elena Diaz-Blanco, Thorsten Graef, MD, Ulrich Steidl, MD, Slawomir Kliszewski, Ingmar Bruns, Frank Neumann, MD, Simone Bork, Ulf Butterweck, Nicole Roes, Benedikt Brors, PhD, Roland Eils, PhD, Guido Kobbe, MD, Norbert Gattermann, MD, Rainer Haas, MD

Blood (2005) 106 (11): 2863.

https://doi.org/10.1182/blood.V106.11.2863.2863

Published: 2005

Journal Articles

Pre-Transplantation Level of Minimal Residual Disease Detected by Quantitative Real-Time IgH-PCR Is a Prognostic Parameter in Patients with Multiple Myeloma.

Roland Fenk, MD, Mark Korthals, Guido Kobbe, MD, Ulrich Steidl, MD, Thorsten Graef, MD, Ulrich-Peter Rohr, MD, Leilani Ruf, MD, Barbara Hoyer, MD, Frank Neumann, MD, Rainer Haas, MD, Ralf Kronenwett, MD

Blood (2004) 104 (11): 4871.

https://doi.org/10.1182/blood.V104.11.4871.4871

Published: 2004

Journal Articles

Transplantation of Peripheral Blood Stem Cells Mobilized by Chemotherapy and Single Dose Pegylated G-CSF in Patients with Multiple Myeloma: Equivalence of 6 mg and 12 mg Pegfilgrastim.

Ingmar Bruns, MD, Ulrich Steidl, MD, Christof Scheid, MD, Kai Hübel, MD, Roland Fenk, MD, Frank Neumann, MD, Rainer Haas, PhD, MD, Guido Kobbe, MD

Blood (2004) 104 (11): 2868.

https://doi.org/10.1182/blood.V104.11.2868.2868

Published: 2004

NARROW

Major Adverse Cardiac, Arterial Occlusive, and Venous Occlusive Events Among Chronic Myeloid Leukemia Patients Prescribed Ponatinib Vs Bosutinib

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Cancer Drivers Affected by Aberrant DNA Methylation in MDS and AML

SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis,

Digital Restriction Enzyme Analysis of Methylation (DREAM) by Next Generation Sequencing Uncovers Epigenetic Disturbances In Acute Myelogenous Leukemia.

Relevance of HLA-C Epitopes C1 and C2 for the Survival of Patients with AML and CML after Allogeneic Blood Stem Cell Transplantation.

Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose Therapy and Autologous Stem Cell Transplantation Is a Prognostic Parameter in Patients with Multiple Myeloma.

Transcriptional Changes Induced by Imatinib and Nilotinib in the Chronic Myelogenous Leukemia (CML) Cell Line K562.

Sequential Induction Chemotherapy, and Early Intensified Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk Myeloid Leukemia.

Escalation Treatment Algorithm with Bortezomib, Dexamethasone and Bendamustine for Patients with Relapsed or Refractory Multiple Myeloma: A Singel Centre Experience.

Molecular Phenotype of Malignant CD34+ Hematopoietic Stem and Progenitor Cells in Chronic Myelogenous Leukemia.

Pre-Transplantation Level of Minimal Residual Disease Detected by Quantitative Real-Time IgH-PCR Is a Prognostic Parameter in Patients with Multiple Myeloma.

Transplantation of Peripheral Blood Stem Cells Mobilized by Chemotherapy and Single Dose Pegylated G-CSF in Patients with Multiple Myeloma: Equivalence of 6 mg and 12 mg Pegfilgrastim.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only